The global deep brain stimulation devices market size was valued at USD 1.56 billion in 2022. It is estimated to reach USD 5.44 billion by 2031, growing at a CAGR of 14.9% during the forecast period (2023–2031).
Deep Brain Stimulation (DBS) devices are medical implants used in neurology to treat certain neurological disorders, particularly movement disorders such as Parkinson's disease, essential tremor, and dystonia. These devices deliver electrical impulses to specific brain areas to modulate abnormal neuronal activity and alleviate symptoms. A typical DBS system consists of three main components: the implanted pulse generator (IPG), the lead, and the extension. The IPG is a small device related to a pacemaker that generates and delivers electrical stimulation.
The lead is implanted in the targeted brain region with multiple electrodes and carries the electrical impulses. The extension connects the IPG to the lead, enabling communication and power supply. Deep brain stimulation devices are crucial in managing movement disorders, providing patients with a viable therapeutic option to alleviate symptoms and improve their daily functioning.
Globally increasing rates of neurological illnesses are expected to fuel the market for deep brain stimulation devices. Based on the information provided by the Parkinson's Foundation, more than 9 million people are affected by Parkinson's globally. The estimates suggest that approximately 930,000 people in the U.S. will be living with Parkinson's by the year 2020. The number is further anticipated to grow to 1.2 million by 2030. Additionally, depression is one of the most prevalent mental illnesses worldwide, according to the WHO. Nearly 300 million people across all ages are suffering from depression. Therefore, all these factors lead to the growth of the market.
The Office of Health Economics released data showing that neurology is one of the highest-cost therapeutic areas for research and development. It costs over USD 1.3 billion to create a single new molecular entity. Therefore, an increase in investment in R&D for neurological disorders is anticipated to drive the global market expansion for deep brain stimulation devices. For instance, in 2018, Takeda Pharmaceuticals collaborated with Denali Therapeutics for USD 155 million for several preclinical programs in Alzheimer's and Parkinson's. Moreover, the same year, Takeda Pharmaceuticals collaborated with Biotech Wave Life Sciences to develop advanced therapies for CNS (Central nervous system) disorders.
Furthermore, the increasing investment in R&D signifies a growing understanding of neurological disorders' rising prevalence and impact, which drives the expansion of deep brain stimulation devices. This focused effort on developing innovative therapies underscores the determination to enhance patient outcomes and improve the overall quality of life for individuals affected by neurological conditions. Such factors are estimated to drive market expansion over the forecast period.
Unfavorable side effects of implanting deep brain stimulation in the body include pain at the implantation site, lead movement, hematoma, paralysis, epidural bleeding, seroma, device malfunctioning, erosion, and infection. Patients must avoid twisting, bending, lifting objects, or stretching post-implantation. Therefore, these risks and side effects may cause malfunctioning of the devices by ineffective or over-stimulation of neural activities resulting in loss of therapy effect, thereby restraining the market growth. Addressing these side effects and risks associated with DBS devices is crucial for ensuring patient safety and improving treatment outcomes. Ongoing advancements in device technology and surgical techniques aim to minimize these risks and enhance deep brain stimulation therapies' overall safety and effectiveness.
The number of conditions for which deep brain stimulators can be helpful has grown as neurology research has progressed. Research regarding the use of deep brain stimulators for managing diseases such as obsessive-compulsive disorders and interstitial cystitis is ongoing. They are expected to create newer opportunities for the development of deep brain stimulation devices in the coming years. One such area of research is using DBS for managing obsessive-compulsive disorders (OCD). OCD is a chronic mental disorder defined by intrusive thoughts and repetitive behaviors.
Furthermore, traditional treatments such as medication and psychotherapy may not relieve all patients sufficiently. As a result, researchers are investigating the potential of DBS in targeting specific brain regions associated with OCD and modulating neural activity to alleviate symptoms. Promising results from early studies have shown the potential efficacy of DBS as a treatment option for OCD, opening up new possibilities for its use. In addition, the ongoing research in these areas and other potential indications for DBS underscores the expanding opportunities for growth in the deep brain stimulation devices market. As more scientific evidence is gathered, regulatory approvals may be obtained for DBS in managing these disorders, leading to increased adoption of deep brain stimulators.
The global market is bifurcated into applications and end users.
Based on application, the global market is bifurcated into Parkinson’s disease, epilepsy, dystonia, essential tremor, obsessive-compulsive disorder, and others.
The Parkinson's disease segment dominates the global market and is expected to exhibit a CAGR of 16.9% over the forecast period. Parkinson's disease is a progressive and chronic nervous system disorder that affects movements and causes the patient to lose control over some bodily functions. Since Parkinson's disease cannot be cured, medications can help control and relieve the symptoms, allowing numerous opportunities for deep brain stimulation to treat PD. Deep brain stimulation devices are usually preferred for patients suffering from PD that relieve symptoms such as tremors, walking difficulties, and balancing issues. Thus, the lower availability of treatment options and growing patient pool associated with PD are the key drivers of the market for Parkinson's disease.
Additionally, the growing patient pool associated with Parkinson's disease contributes to the market growth. The prevalence of Parkinson's disease is increasing globally, primarily due to aging populations and improved diagnosis rates. As more individuals are diagnosed with Parkinson's, the demand for effective treatment options like deep brain stimulation is rising.
Based on end-users, the global market is bifurcated into hospitals, ambulatory surgical centers, neurological clinics, and others.
The hospital segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 17.1% over the forecast period. The hospital segment of the market holds the largest market share due to several factors. Firstly, brain monitoring is a complex process that requires advanced and expensive devices and equipment. These resources are primarily available in hospitals with the infrastructure and resources to support the installation and maintenance of such equipment. Hospitals have the necessary expertise and personnel to perform brain monitoring procedures and handle the associated complexities. Secondly, brain stimulation devices, which are used in conjunction with brain monitoring, also impose a significant financial burden in terms of maintenance expenses on healthcare facilities. Hospitals, being larger and better funded than small clinics and other healthcare settings, are better positioned to bear these costs.
Furthermore, brain monitoring is a multifaceted process that necessitates using sophisticated and costly devices and equipment, typically found in hospital settings. Further, brain stimulation devices place a significant financial burden on healthcare facilities regarding maintenance expenses. Among various end-users, hospitals are better equipped to handle these costs. Moreover, hospitals handle a larger influx of patients compared to smaller clinics and other end users. As a result, brain stimulation devices are predominantly utilized in hospitals, thus accounting for the largest market share.
Based on region, the global market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America is the most significant global market shareholder and is estimated to exhibit a CAGR of 13.91% over the forecast period. North America constitutes three major countries: the U.S., Canada, and Mexico. U.S. market accounts for the major share of the total market, owing to the increase in the prevalence of various neurological diseases such as Parkinson's disease, depression, and epilepsy. For example, as per the National Institute of Mental Health "Major Depression," 2017, depression affects around 17.3 million adults in America, around 7.1% of the U.S. population annually. In addition, there is increased awareness regarding using deep brain stimulators to treat neurological disorders. Private and government organizations have undertaken various initiatives to raise awareness about chronic pain management and neurological disorders in the region. The desire to increase life quality is high in the U.S., which leads to increased acceptance of deep brain stimulators for pain management and treatment of depression.
Furthermore, technological advancements in deep brain stimulator devices have fueled the growth of the region's market. The elements, including rising rates of neurological conditions, growth in the geriatric population, and recent approvals of deep brain stimulators by Health Canada, are expected to drive the market growth. Deep brain stimulation equipment sales are anticipated to rise in Mexico due to increased healthcare expenditure and growth in awareness of deep brain stimulators.
Europe is estimated to exhibit a CAGR of 16.5% over the forecast period. European market is studied concerning five major countries: Germany, France, the U.K., Italy, Spain, and the rest of Europe. Europe occupies the second highest market share in the global market, after North America. Germany holds the major market share in Europe's market, followed by France, the U.K., Italy, and others. The deep brain stimulation devices market in Germany has witnessed steady growth due to factors such as the rise in the incidence of neurological disorders in the region.
In addition, Germany has the highest prevalence of Parkinson's disease in Europe, according to the Competence Network on Parkinson's Disease, a German national network supported by the Federal Ministry of Education and Research. Moreover, per the European Brain Council (EBC) data, 1.2 million people in Europe have Parkinson's disease. Germany accounted for 260,000, Italy accounted for 200,000, Spain accounted for 150,000, the U.K. accounted for 120,000, and France accounted for 117,000. Deep brain stimulation devices are ideal for managing the symptoms associated with neurological disorders; hence, there is lucrative scope for market players in Europe.
The Asia-Pacific region, consisting of Australia, Japan, India, China, and the rest of Asia-Pacific, provides attractive opportunities for players in the market, with expectations of being the fastest-growing market. Market growth is driven by government and private initiatives to increase mental health awareness and the rising incidence of neurological disorders. China holds the largest share in the region, followed by Japan. In addition, India is anticipated to experience significant growth due to increased awareness of mental disorders and higher healthcare spending.
In LAMEA, the rise in incidences of neurological disorders coupled with the rapidly growing senior population drives the rise of the market. In addition, growing research and development activities to treat neurological disorders are expected to strengthen the market growth. Latin America has a high prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, and epilepsy. Pain management offers a huge market for deep brain stimulation devices. However, there are unmet requirements in this region's due to the countries' lack of efficient treatment systems.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
"Find new revenue generation opportunities"